Previous close | 44.08 |
Open | 44.08 |
Bid | 49.05 |
Ask | 51.40 |
Strike | 80.00 |
Expiry date | 2024-05-17 |
Day's range | 44.08 - 44.08 |
Contract range | N/A |
Volume | |
Open interest | 22 |
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...